What is HER2+ unresectable or metastatic breast cancer?

number one
HER2 tells cells to grow
HER2 is a protein that tells cells to grow. In HER2+ breast cancer, the cancer cells have too much HER2, which leads to cancer growth.
number two
Tumors form
These cancer cells grow and divide faster than healthy cells, causing tumors to form.
number three
Cancer may spread
HER2+ breast cancer can spread to other parts of the body. This is known as HER2+ metastatic breast cancer (or HER2+ mBC). HER2+ unresectable breast cancer means it cannot be removed by surgery.

What is ENHERTU?

ENHERTU is a prescription medicine for adults with HER2+ breast cancer:

  • That cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 metastatic breast cancer treatment:
    • for metastatic disease, or
    • have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer

It is not known if ENHERTU is safe and effective in children.

ENHERTU was studied in many types of people, including those with different:

  • Ages
  • Hormone receptor (HR) status
  • Tumors that had spread (metastasized) to other parts of the body, including the liver, lungs, and bone
  • Tumors that had spread to the brain and were stable

How is ENHERTU thought to work?

As a type of targeted treatment called an antibody-drug conjugate (ADC), ENHERTU is designed to work differently than traditional chemotherapies.

ENHERTU is made up
of an antibody with a
chemotherapy attached
The antibody part of
ENHERTU targets and
attaches to the HER2+
cancer cell
ENHERTU enters
the cancer cell and the
chemotherapy is released
The chemotherapy part
of ENHERTU helps
destroy the cancer cell
as well as other
cells nearby

Although ENHERTU is designed to target HER2+ cancer cells, it may affect some healthy cells.
ENHERTU may not work for everyone.

How will I receive ENHERTU?

ENHERTU is taken alone, without the need for other medicines, to treat metastatic breast cancer

ENHERTU is given as an intravenous infusion (IV) once every 3 weeks

  • ENHERTU has a treatment schedule that may be similar to other medicines you may have been prescribed before
The first infusion will take
about 90 minutes so the
doctor can see if there are
any side effects or problems
Future infusions should
take about 30 minutes,
if your first infusion was well tolerated

To help manage your side effects, your healthcare provider may:

Lower your dose

Delay your dose


Your healthcare provider will give you medicines before your infusion to help prevent nausea and vomiting.

Would you like to receive updates
about ENHERTU?

HER2, human epidermal growth factor 2; mBC, metastatic breast cancer.

Photo of woman in confident pose: With ENHERTU® (fam-trastuzumab deruxtecan-nxki), I stand determined. Photo of woman in confident pose: With ENHERTU® (fam-trastuzumab deruxtecan-nxki), I stand determined. Photo of woman in confident pose: With ENHERTU® (fam-trastuzumab deruxtecan-nxki), I stand determined.
Not an actual patient.